Skip to main content

Dietary Supplements A Framework for Evaluating Safety (2005) / Chapter Skim
Currently Skimming:

Appendix E: Glucosamine: Prototype Monograph Summary
Pages 363-366

The Chapter Skim interface presents what we've algorithmically identified as the most significant single chunk of text within every page in the chapter.
Select key terms on the right to highlight them within pages of the chapter.


From page 363...
... Thus some pertinent information not available to the Committee could be of importance in evaluating safety to determine if use of this dietary supplement ingredient would present an unreasonable risk of illness or injury. Also, the development and review of this prototype was conducted by individuals whose backgrounds are in general aspects of evaluating science and whose expertise is not necessarily focused specifically on this dietary ingredient, although significant additional assistance was provided by consultants with relevant expertise.
Read the entire page →
From page 364...
... Many of the trials relied only on passive reporting. In the placebo-controlled trials, the incidence of adverse effects among the treatment arms was almost identical, while in the NSAID comparison trials, adverse effect rates were higher among those taking NSAIDs (range of 15­ 35 percent)
Read the entire page →
From page 365...
... interpretation of animal and human data indicating that very little intact glucosamine is found in the bloodstream following oral ingestion and thus the secretion problems observed following millimolar blood concentrations in rats would not occur in humans following ingestion,2 and (2) lack of many consistent overt serious effects reported in clinical trials.
Read the entire page →
From page 366...
... . All future trials should have a systematic collection, evaluation, and reporting of adverse events, and key data relevant to addressing the gaps in knowledge should be collected and reported.
Read the entire page →

Key Terms

  • increased glucosamine
  • insulin resistance
  • supplement ingredient
  • glucosamine intake
  • oral administration

  • following oral
  • systematic collection
  • effects reported
  • insulin secretion
  • ingested glucosamine

  • glucose metabolism
  • human study
  • animal studies
  • studies using
  • little intact

  • joint pain
  • consistent overt
  • future trials
  • pancreatic islet
  • relevant blood

  • orally ingested
  • pertinent information
  • data concerning
  • glucosamine administered
  • clinical trials

  • liver disease
  • chronic joint
  • observed following
  • format described
  • rapidly absorbed


    • This material may be derived from roughly machine-read images, and so is provided only to facilitate research.
    More information on Chapter Skim is available.